United States - English - NLM (National Library of Medicine)

apotex corp. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - duloxetine delayed-release capsules are indicated for the treatment of: - major depressive disorder in adults - generalized anxiety disorder in adults and pediatric patients 7 years of age and older - diabetic peripheral neuropathic pain in adults - fibromyalgia in adults and pediatric patients 13 years of age and older - chronic musculoskeletal pain in adults the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)]. starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of ser

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 60 mg - duloxetine delayed-release capsules are indicated for the treatment of: - major depressive disorder [see clinical studies ( 14.1)] - generalized anxiety disorder [see clinical studies ( 14.2)] - diabetic peripheral neuropathy [see clinical studies ( 14.3)] - chronic musculoskeletal pain [see clinical studies ( 14.5)] monoamine oxidase inhibitors (maois) the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration ( 2.8) and warnings and precautions ( 5.4)]. starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of ser

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 30 mg - duloxetine delayed-release capsules are indicated for the treatment of: - major depressive disorder [see clinical studies (14.1)] - generalized anxiety disorder [see clinical studies (14.2)] - diabetic peripheral neuropathy [see clinical studies (14.3)] - chronic musculoskeletal pain [see clinical studies (14.5)] monoamine oxidase inhibitors (maois) the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.8) and warnings and precautions (5.4)]. starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 30 mg - duloxetine delayed-release capsules are indicated for the treatment of: - major depressive disorder [see clinical studies ( 14.1)] - generalized anxiety disorder [see clinical studies ( 14.2)] - diabetic peripheral neuropathy [see clinical studies ( 14.3)] - chronic musculoskeletal pain [see clinical studies ( 14.5)] monoamine oxidase inhibitors (maois) the use of maois intended to treat psychiatric disorders with duloxetine delayed-release capsules or within 5 days of stopping treatment with duloxetine delayed-release capsules is contraindicated because of an increased risk of serotonin syndrome. the use of duloxetine delayed-release capsules within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration ( 2.8) and warnings and precautions ( 5.4)]. starting duloxetine delayed-release capsules in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of ser

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - duloxetine hydrochloride (unii: 9044sc542w) (duloxetine - unii:o5tnm5n07u) - duloxetine 20 mg - duloxetine delayed-release capsules usp, are indicated for the treatment of major depressive disorder (mdd). the efficacy of duloxetine delayed-release capsules, usp was established in four short-term and one maintenance trial in adults [see clinical studies (14.1)] . a major depressive episode (dsm-iv) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. duloxetine delayed-release capsules, usp are indicated for the treatment of generalized anxiety disorder (gad). the efficacy of duloxetine delayed-release capsules, usp was established in three short-

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 33.65 mg - capsule, enteric - excipient ingredients: hypromellose; purified talc; gelatin; sucrose; indigo carmine; hypromellose phthalate; triethyl citrate; titanium dioxide; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; iron oxide yellow; shellac; strong ammonia solution - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad). duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - duloxetine hydrochloride, quantity: 67.3 mg - capsule, enteric - excipient ingredients: titanium dioxide; gelatin; hypromellose; purified talc; hypromellose phthalate; triethyl citrate; indigo carmine; sucrose; iron oxide yellow; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide; maize starch - duloxetine capsules are indicated for the - treatment of major depressive disorder (mdd). - treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 67.32 mg (equivalent: duloxetine, qty 60 mg) - capsule, enteric - excipient ingredients: titanium dioxide; hyprolose; hypromellose; crospovidone; triethyl citrate; hypromellose phthalate; purified talc; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; iron oxide yellow; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - duloxetine hydrochloride, quantity: 67.32 mg (equivalent: duloxetine, qty 60 mg) - capsule, enteric - excipient ingredients: purified talc; hypromellose phthalate; triethyl citrate; titanium dioxide; hyprolose; hypromellose; crospovidone; maize starch; sucrose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; indigo carmine; iron oxide yellow; gelatin; sodium lauryl sulfate - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - duloxetine hydrochloride, quantity: 33.66 mg (equivalent: duloxetine, qty 30 mg) - capsule, enteric - excipient ingredients: titanium dioxide; crospovidone; hypromellose phthalate; hypromellose; triethyl citrate; purified talc; hyprolose; maize starch; sucrose; indigo carmine; purified water; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - duloxetine is indicated for the treatment of major depressive disorder (mdd).,duloxetine is indicated for the treatment of generalised anxiety disorder (gad).